Week of March 7th 2022 | Vol. 11, Issue 10
|
|
|
In This Issue
Upcoming Events
Industry M&A Activity
Recent Transactions
Trading Comps
Market Reports
M&A Pipeline
Featured Headlines
Tanner Updates
Quick Links
Contact Information
Managing Director
Business Development
Managing Director
Head of M&A and Capital Advisory
|
|
Above is an overview of recent industry M&A activity. Click on the chart to download complete transaction tables broken out by industry sub sectors. For additional information, see the Industry M&A Activity section below.
|
|
Events Hosted or Attended by Bourne Partners
|
|
|
March 16-18, 2022 - Aventura, FL
|
|
|
March 21-24, 2022 - New York City, NY
|
|
|
May 17-19, 2022 - Philadelphia, PA
|
|
|
May 24-26, 2022 - New York City, NY
|
|
|
April 23-26, 2022 - Palm Beach, FL
|
|
|
June 13-16, 2022 - San Diego, CA
|
|
|
April 23-26, 2022 - Palm Beach, FL
|
|
|
October 2022 - Charlotte, NC
|
|
INDUSTRY M&A ACTIVITY
Recent Transactions, Trading Comps, Market Reports, M&A Pipeline
|
|
RECENT TRANSACTIONS
An Overview of Transactions Within Market Sub-segments
|
|
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
|
|
|
Pharma & Biotech
7 transactions totaling $4,409 million
Supplies, Equipment & Services
11 transactions totaling $294 million
Healthcare IT & Managed Care
6 transactions totaling $2 million
Healthcare Facilities & Distributors
5 transactions totaling $2 million
|
|
|
Pharma & Biotech
24 transactions totaling $441 million
Supplies, Equipment & Services
15 transactions totaling $839 million
Healthcare IT & Managed Care
14 transactions totaling $200 million
Healthcare Facilities & Distributors
4 transactions totaling $41 million
|
|
|
Pharma & Biotech
20 transactions totaling $2,456 million
Supplies, Equipment & Services
3 transactions totaling $70 million
Healthcare IT & Managed Care
2 transactions totaling $9 million
Healthcare Facilities & Distributors
8 transactions totaling $6,031 million
|
|
TRADING COMPS
A Breakdown of Relevant Trading Multiples
|
|
|
This is a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.
For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table.
Note: data reflects prior week close.
|
|
MARKET REPORTS
Insight Into Healthcare Related Industries
|
|
M&A PIPELINE
Representative Current Retained Sell-Side And Partnering Opportunities
|
|
Project Focus
Sell-side | CMO | Liquids and Semi-solids CMO headquartered in North America
Project Nucleus
Buy-side| CDMO | North American radiopharmaceutical company
|
|
Project Power Play
Buy-side | Specialty Pharma | In-license and acquire approved Rx products including legacy brands, generics, and niche launch-ready products
Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics
|
|
FEATURED HEADLINES
A Sampling of Industry Headlines From Last Week
|
|
Bourne Partners (“Bourne”), a leading financial services firm specializing in the pharma, pharma services, OTC and consumer health sectors announced the appointment of Dr. Martin Zentgraf, as a Senior Advisor to the firm.
Based in Hamburg, Germany, Martin has 35 years of leadership in the European pharma and medtech industry, including 6 years as chairman of the Federal Association of the Pharmaceutical Industry and more than 10 years as a Board Member. Most recently, Martin was the Managing Director and Speaker of the Board of management of Desitin Arzneimittel GmbH, a European specialty pharmaceutical company focused on the CNS and rare diseases markets. While at Desitin he was responsible generally for the whole company with a focus on strategic direction, M&A and other business development initiatives and for the commercial organization.
|
|
March 2, 2022 - Fierce Biotech
|
Sanofi seems to be in a betting mood and has been picking up card after card in licensing deals to bulk up its early-stage pipeline.
|
|
March 2, 2022 - Fierce Biotech
|
When Christopher Austin, M.D., and Doug Cole, M.D., were co-residents at Massachusetts General Hospital in the late '80s, they realized the diagnoses and treatments for common diseases were "both problematic."
|
|
March 2, 2022- Fierce Healthcare
|
This morning, the Biden administration released a 96-page strategy outlining tactics to mitigate COVID-19 cases and prepare for future surges with limited shutdowns.
|
|
March 3, 2022- Fierce Pharma
|
The contingent of biotech and pharma companies condemning Russia’s invasion of Ukraine—and pledging to help keep the beleaguered nation’s healthcare system afloat—is growing.
|
|
|
Discover more about the connection between real-world data capture and early access programs, and the role this plays in the approval of life-improving medicines.
|
|
|
|
|
|
|